Physician profile
Beverly Held
NPI 1477544211
$598.94
in general payments reported to CMS, 2019-2025
12 companies · $58.29 in 2025
The $58.29 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $52.75 · 2021: $63.81 · 2022: $213 · 2023: $65.56 · 2024: $26.85 · 2025: $58.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $137.53 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $97.93 | 2021-2025 | |
| Galderma Laboratories, L.P. | $73.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.41 | 2023-2024 | Sotyktu |
| Aclaris Therapeutics, INC. | $40.18 | 2019 | |
| Sebela Pharmaceuticals INC. | $30.22 | 2019 | |
| Leo Pharma INC. | $30.00 | 2020 | |
| Janssen Biotech, INC. | $29.48 | 2022 | |
| Janssen Scientific Affairs, LLC | $26.78 | 2021 | |
| Amgen INC. | $25.00 | 2023 | Otezla |
| Genzyme Corporation | $22.75 | 2020 | |
| Mayne Pharma Commercial LLC | $18.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Held listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.